Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13618
UPID:
CUL3_HUMAN
Alternative names:
-
Alternative UPACC:
Q13618; A8K536; B8ZZC3; O75415; Q569L3; Q9UBI8; Q9UET7
Background:
Cullin-3, a core component of multiple cullin-RING-based BCR E3 ubiquitin-protein ligase complexes, plays a pivotal role in protein ubiquitination and degradation. It regulates various biological processes, including ion transport, cell cycle progression, and signal transduction, by targeting specific proteins for proteasomal degradation.
Therapeutic significance:
Cullin-3's involvement in diseases like Pseudohypoaldosteronism 2E and Neurodevelopmental disorder with or without autism or seizures highlights its potential as a therapeutic target. Understanding Cullin-3's role could pave the way for novel treatments for these conditions.